Skip to main content
Book cover

ADAMTS13 pp 129–139Cite as

Thrombotic Microangiopathies and Their Distinction from TTP

  • Chapter
  • 532 Accesses

Abstract

Thrombotic microangiopathies (TMAs) comprise a number of distinct disorders with shared findings of platelet thrombi within small arterioles with resultant thrombocytopenia and mechanical destruction of red blood cells within small vessels. For many forms of TMA, including thrombotic thrombocytopenic purpura (TTP), effective treatment exists but must be instituted without undue delay, and the treatment itself may be costly and not without risk.

This chapter will highlight distinguishing characteristics of TTP, with an emphasis on efficient and accurate diagnosis through appropriate laboratory testing and early recognition of clinical features. Differentiating TTP from hemolytic-uremic syndrome (HUS) poses a particular challenge and will be discussed in some detail. Other forms of TMA will be reviewed more briefly, and a suggested diagnostic algorithm is presented.

Keywords

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–103.

    CAS  PubMed  Google Scholar 

  2. Furlan M, Robles R, Solenthaler M, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839–46.

    CAS  PubMed  Google Scholar 

  3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost. 2003;29:479–88.

    Article  CAS  PubMed  Google Scholar 

  5. Tsai HM. Thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome and related disorders. In: Greer JP, Foerster J, Rodgers GM, editors. Wintrobe’s clinical hematology. 12th ed. Philadelphia: Lippincott Williams & Williams; 2008. p. 1314–21.

    Google Scholar 

  6. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–7.

    Article  CAS  PubMed  Google Scholar 

  7. Bentley MJ, Lehman CM, Blaylock RC, et al. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion. 2010;50:1654–64.

    Article  CAS  PubMed  Google Scholar 

  8. Bentley MJ, Wilson AR, Rodgers GM. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort. Vox Sang. 2013;105:313–8.

    Article  CAS  PubMed  Google Scholar 

  9. Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol. 2012;157(4):501–2.

    Article  CAS  PubMed  Google Scholar 

  10. Zuber J, Fakhouri F, Roumeninia LT, et al. on behalf of the French Study Group. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–57.

    Google Scholar 

  11. Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014;5:15–23.

    PubMed Central  PubMed  Google Scholar 

  12. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924;24:21–4.

    Google Scholar 

  13. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.

    Article  CAS  PubMed  Google Scholar 

  14. Vessely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–8.

    Article  Google Scholar 

  15. George JN. How I, treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060–9.

    Article  CAS  PubMed  Google Scholar 

  16. Legendre CM, Licht C, Muus LA, et al. Terminal complement inhibitor Eculizumab in a typical hemolytic–uremic syndrome. N Engl J Med. 2013;368:2169–81.

    Article  CAS  PubMed  Google Scholar 

  17. Nguyen L, Terrell DR, Duvall D, et al. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion. 2009;49:392–4.

    Article  PubMed  Google Scholar 

  18. Michon B, Moghrabi A, Winikoff R, et al. Complications of apheresis in children. Transfusion. 2007;47:1837–42.

    Article  PubMed  Google Scholar 

  19. Norris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622–33.

    Article  Google Scholar 

  20. Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations. World J Nephrol. 2013;2(3):56–76.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome? J Am Soc Nephrol. 2001;18:2457–60.

    Article  Google Scholar 

  22. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073–86.

    CAS  PubMed  Google Scholar 

  23. Bitzan M, Schaefer F, Reymond D. Treatment of typical (Enteropathic) hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:594–610.

    Article  CAS  PubMed  Google Scholar 

  24. Bantavala N, Griffin PM, Greene KD, et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis. 2001;183:1063–70.

    Article  Google Scholar 

  25. Karpman D, Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie. 2013;33:96–104.

    Article  CAS  PubMed  Google Scholar 

  26. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–87.

    Article  CAS  PubMed  Google Scholar 

  27. Sallee M, Simail K, Fakhouri F. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrology 2013;14:3. http://www.biomedcentral.com/1471-2369/14/3.

  28. Norris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–59.

    Article  Google Scholar 

  29. Caprioli J, Norris M, Briochi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Knobl P. Treatment of thrombotic microangiopathy with a focus on new treatment options. Hamostaseologie. 2013;33:149–59.

    Article  CAS  PubMed  Google Scholar 

  31. Kapiteijn E, Brand A, Kroep J, et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukoencephalopathy syndrome. Ann Oncol. 2007;18:1745–7.

    Article  CAS  PubMed  Google Scholar 

  32. Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med. 1984;101:41–4.

    Article  CAS  PubMed  Google Scholar 

  33. Appel GB, Pirani CL, D’Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994;4:1499–515.

    CAS  PubMed  Google Scholar 

  34. Jacobson RJ, Rath CE, Perloff JK. Intravascular haemolysis and thrombocytopenia in left ventricular outflow obstruction. Br Heart J. 1973;35:849–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost. 1985;11:249–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Melissa J. Bentley M.D., F.A.C.P. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bentley, M.J. (2015). Thrombotic Microangiopathies and Their Distinction from TTP. In: Rodgers, G. (eds) ADAMTS13. Springer, Cham. https://doi.org/10.1007/978-3-319-08717-7_7

Download citation

Publish with us

Policies and ethics